6FV Stock Overview
Operates as a medtech and clinical-stage pharmaceutical company that develops antimicrobials products for infection prevention and treatment in Norway. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
SoftOx Solutions AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 0.01 |
| 52 Week High | NOK 0.012 |
| 52 Week Low | NOK 0.0002 |
| Beta | 1.78 |
| 1 Month Change | 233.33% |
| 3 Month Change | 900.00% |
| 1 Year Change | 0% |
| 3 Year Change | -99.72% |
| 5 Year Change | n/a |
| Change since IPO | -99.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6FV | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 11.1% | -0.5% | 0.7% |
| 1Y | 0% | -18.0% | 13.8% |
Return vs Industry: 6FV exceeded the German Pharmaceuticals industry which returned -18% over the past year.
Return vs Market: 6FV underperformed the German Market which returned 13.8% over the past year.
Price Volatility
| 6FV volatility | |
|---|---|
| 6FV Average Weekly Movement | 152.7% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 6FV's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6FV's weekly volatility has decreased from 743% to 153% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 7 | Thomas Bjarnsholt | soft-ox.com |
SoftOx Solutions AS, together with its subsidiaries, operates as a medtech and clinical-stage pharmaceutical company that develops antimicrobials products for infection prevention and treatment in Norway. Its products include SafeDes+, a hand disinfectant for irritated, compromised, and eczematous skin; and EffectDesH, a surface disinfectant, which has a killing/inactivation effect on bacteria, viruses, yeast, fungi, mycobacterium, and spores. The company also provides human wound and infection treatment products comprising SoftOx Wound Irrigation solutions for acute and chronic wounds to prevent and treat infections, including biofilms; and SoftOx Anti-infectives to treat and remove topical infections in wounded and mucosal tissues, such as biofilms, AMR microbes, viruses, and fungi.
SoftOx Solutions AS Fundamentals Summary
| 6FV fundamental statistics | |
|---|---|
| Market cap | €25.73m |
| Earnings (TTM) | -€4.36m |
| Revenue (TTM) | €683.36k |
37.7x
P/S Ratio-5.9x
P/E RatioIs 6FV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6FV income statement (TTM) | |
|---|---|
| Revenue | NOK 7.91m |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 7.91m |
| Other Expenses | NOK 58.37m |
| Earnings | -NOK 50.46m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Jun 10, 2025
| Earnings per share (EPS) | -0.023 |
| Gross Margin | 100.00% |
| Net Profit Margin | -637.59% |
| Debt/Equity Ratio | 0% |
How did 6FV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/13 23:38 |
| End of Day Share Price | 2025/05/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SoftOx Solutions AS is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.